Vinpocetine is a poorly water soluble weakly basic drug (pKa = 7.1) used for the treatment of several cerebrovascular and cognitive disorders. Because existing formulations exhibit poor bioavailability and scarce absorption, a dosage form with improved pharmacokinetic properties is highly desirable. Cocrystallization represents a promising approach to generate diverse novel crystal forms and to improve the aqueous solubility and in turn the oral bioavailability. In this article, a novel ionic cocrystal of vinpocetine is described, using boric acid as a coformer, and fully characterized (by means of differential scanning calorimetry, solid-state nuclear magnetic resonance, powder and single-crystal X-ray diffraction, and powder dissolution test). Pharmacokinetic performance was also tested in a human pilot study. This pharmaceutical ionic cocrystal exhibits superior solubilization kinetics and modulates important pharmacokinetic values such as maximum concentration in plasma (Cmax), time to maximum concentration (tmax), and area under the plasma concentration-time curve (AUC) of the poorly soluble vinpocetine and it therefore offers an innovative approach to improve its bioavailability.

Improving Biopharmaceutical Properties of Vinpocetine Through Cocrystallization

CHIEROTTI, Michele Remo;
2016-01-01

Abstract

Vinpocetine is a poorly water soluble weakly basic drug (pKa = 7.1) used for the treatment of several cerebrovascular and cognitive disorders. Because existing formulations exhibit poor bioavailability and scarce absorption, a dosage form with improved pharmacokinetic properties is highly desirable. Cocrystallization represents a promising approach to generate diverse novel crystal forms and to improve the aqueous solubility and in turn the oral bioavailability. In this article, a novel ionic cocrystal of vinpocetine is described, using boric acid as a coformer, and fully characterized (by means of differential scanning calorimetry, solid-state nuclear magnetic resonance, powder and single-crystal X-ray diffraction, and powder dissolution test). Pharmacokinetic performance was also tested in a human pilot study. This pharmaceutical ionic cocrystal exhibits superior solubilization kinetics and modulates important pharmacokinetic values such as maximum concentration in plasma (Cmax), time to maximum concentration (tmax), and area under the plasma concentration-time curve (AUC) of the poorly soluble vinpocetine and it therefore offers an innovative approach to improve its bioavailability.
105
12
3626
3633
http://jpharmsci.org/article/S0022-3549(16)41711-9/abstract
bioavailability; boric acid; ionic cocrystal; pharmacokinetics; vinpocetine
Golob, Samuel; Perry, Miranda; Lusi, Matteo; Chierotti, Michele R; Grabnar, Iztok; Lassiani, Lucia; Voinovich, Dario; Zaworotko, Michael J
File in questo prodotto:
File Dimensione Formato  
open access.docx

Open Access dal 16/11/2017

Descrizione: versione open access postprint
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 922.14 kB
Formato Microsoft Word XML
922.14 kB Microsoft Word XML Visualizza/Apri
j pharm sci2016,105,3626_completo.pdf

Accesso riservato

Descrizione: articolo completo pubblicato
Tipo di file: PDF EDITORIALE
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1611995
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 24
social impact